Therapeutic Drug Monitoring in Infants and Children

Garg, Uttam; Frazee, C. Clinton

doi:10.1016/b978-0-12-802025-8.00007-6

Cited by 4 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TDM could help to optimize drug exposure for clinical efficacy and to prevent toxicity [2]. Therefore, therapeutic drug monitoring (TDM) should be adopted in NICUs, where the most preterm and fragile babies are hospitalized and treated with many drugs [3]. This review provides an overview of the latest advances in this field, showing options for a personalized therapy in this delicate patient population.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age

Rose

Cairoli

Dionisi

et al. 2020

IJMS

View full text Add to dashboard Cite

Therapeutic drug monitoring (TDM) should be adopted in all neonatal intensive care units (NICUs), where the most preterm and fragile babies are hospitalized and treated with many drugs, considering that organs and metabolic pathways undergo deep and progressive maturation processes after birth. Different developmental changes are involved in interindividual variability in response to drugs. A crucial point of TDM is the choice of the bioanalytical method and of the sample to use. TDM in neonates is primarily used for antibiotics, antifungals, and antiepileptic drugs in clinical practice. TDM appears to be particularly promising in specific populations: neonates who undergo therapeutic hypothermia or extracorporeal life support, preterm infants, infants who need a tailored dose of anticancer drugs. This review provides an overview of the latest advances in this field, showing options for a personalized therapy in newborns and infants.

show abstract

Section: Introductionmentioning

confidence: 99%